Two recalls of compounded tirzepatide drew national news coverage on October 19, 2026. The recalls cover specific lots from two compounding firms, Apothecary Pharma LLC and Houston Rx LLC. The FDA classified both as Class II recalls, and the stated reason for each is lack of assurance of sterility.
Brand-name Mounjaro (tirzepatide) and Zepbound (tirzepatide) are not part of either recall. The recalls cover compounded products only. Compounded drugs are not FDA-approved.
What a Class II Recall Means
The FDA uses Class II for a recall where use of the product may cause temporary or medically reversible health consequences, or where the probability of serious adverse health consequences is remote. A Class II recall is not a finding that the product was contaminated. Lack of assurance of sterility means the FDA record does not show that sterility was assured for the listed lots.
Recall 1: Apothecary Pharma
Apothecary Pharma LLC of Cary, North Carolina, a 503B outsourcing facility, voluntarily recalled Tirzepatide Injection, 18 mg/mL, in 4 mL sterile multi-dose vials (NDC 85091-001-18). The firm initiated the recall on September 24, 2026, notified customers by letter, and the FDA classified it Class II on October 8, 2026. The FDA Enforcement Report date is October 14, 2026 (recall D-0036-2027, event 99952). Distribution is listed as nationwide in the United States. The recall status is ongoing.
The recall covers 22 vials across 22 lots. The lot numbers are AP-202622 through AP-202625 and AP-202627 through AP-202644. Lot AP-202626 is not on the FDA list.
Full Apothecary Tirzepatide Lot List
The table below reproduces the lot numbers and beyond-use dates from the FDA enforcement record (D-0036-2027).
| Lot number | Beyond-use date |
|---|---|
| AP-202622 | October 7, 2026 |
| AP-202623 | October 8, 2026 |
| AP-202624 | October 19, 2026 |
| AP-202625 | October 20, 2026 |
| AP-202627 | October 26, 2026 |
| AP-202628 | October 27, 2026 |
| AP-202629 | October 28, 2026 |
| AP-202630 | October 31, 2026 |
| AP-202631 | November 1, 2026 |
| AP-202632 | November 3, 2026 |
| AP-202633 | November 7, 2026 |
| AP-202634 | November 8, 2026 |
| AP-202635 | November 16, 2026 |
| AP-202636 | November 17, 2026 |
| AP-202637 | November 18, 2026 |
| AP-202638 | November 19, 2026 |
| AP-202639 | November 20, 2026 |
| AP-202640 | November 21, 2026 |
| AP-202641 | November 22, 2026 |
| AP-202642 | November 24, 2026 |
| AP-202643 | November 25, 2026 |
| AP-202644 | November 26, 2026 |
NAD+ Lot in the Same Recall Event
The same FDA event (99952) includes one vial of Apothecary NAD+ Injection, 200 mg/mL, in a 6 mL sterile multi-dose vial (NDC 85091-011-06). Lot AP-202647, beyond-use date October 13, 2026, is recalled for the same reason, lack of assurance of sterility (recall D-0037-2027). The firm initiated this recall on September 24, 2026, and the FDA classified it Class II on October 8, 2026.
Practical side-effect tips, one email a week
Nausea, constipation, fatigue and more: food-first fixes and questions worth asking your prescriber. Free.
Check Your Vial
If you received compounded tirzepatide from Apothecary Pharma, check the lot number printed on your vial label against the table above.
- If your lot number matches a listed lot, do not use the vial. Contact the pharmacy or prescriber that dispensed it and ask for the recall instructions and a replacement.
- If your lot number is AP-202626, it is not on the FDA list. The FDA list is the reference, not the lot range alone.
- If you received compounded tirzepatide from another compounder, your product is not covered by this recall. Check the lot number against the FDA record for your compounder.
- If you used a recalled lot and have symptoms, contact your prescriber or seek care, and report the event to the FDA MedWatch program.
Recall 2: Houston Rx
Houston Rx LLC of Houston, Texas, a 503A pharmacy, voluntarily recalled Tirzepatide/Niacinamide 2 mL vials (40 mg per vial), 20 mg/2 mg per mL. The affected lot is TZN-080326-20/2-2, beyond-use date December 1, 2026. The recall covers 64 vials. The firm initiated the recall on September 25, 2026, and the FDA classified it Class II on October 13, 2026. The FDA Enforcement Report date is October 21, 2026 (recall D-0040-2027, event 99990). Distribution is listed as nationwide in the United States. The recall status is ongoing.
The same Houston Rx recall event also covers 7 vials of sermorelin, 1 mg/mL, lot SER-081726-1-10, beyond-use date October 1, 2026 (recall D-0041-2027), for the same reason.
If your vial is Houston Rx tirzepatide with niacinamide, check the lot number on the label. If it reads TZN-080326-20/2-2, do not use it. Contact the pharmacy or prescriber that dispensed it and ask for the recall instructions and a replacement.
A Third Related Recall the Same Week
Carolina Infusion, LLC of Ridgeland, South Carolina, also had compounded tirzepatide and semaglutide syringes classified as a Class II recall for lack of assurance of sterility, with the FDA classification dated October 8, 2026. That recall covers patient-specific syringes, not vials, and is a separate FDA event from the two recalls above.
Import Alert 66-80: The Supply-Chain Context
The recalls arrived while the FDA was tightening control over the raw ingredients compounders use. Import Alert 66-80, titled "Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances," lets the FDA detain foreign shipments of GLP-1 bulk drug substances without physical examination unless the manufacturer and product are on the FDA Green List.
The FDA published a major revision of Import Alert 66-80 on October 9, 2026, updating the Green List criteria and adding product codes, including one for orforglipron. The alert covers bulk drug substances, the raw ingredients compounders import, not finished vials a patient holds. Reporting on the FDA program noted the agency evaluated 48 registered GLP-1 active ingredient manufacturing sites and found 21% out of compliance with federal drug manufacturing standards.
Import Alert 66-80 does not change the status of the recalled lots above. It is a separate enforcement tool aimed at the ingredient supply chain. A Green List entry reflects what a supplier showed about an earlier shipment, not a guarantee about a specific lot a pharmacy received.
What to Do Next
- Check the lot number on every compounded tirzepatide vial you hold against the lists in this article.
- Do not use a vial from a recalled lot. Contact the dispensing pharmacy or your prescriber for recall instructions.
- Keep the vial and its label until the pharmacy tells you what to do with it.
- Ask your pharmacy where it sources its tirzepatide active ingredient and whether the supplier is on the FDA Green List under Import Alert 66-80.
- If you want to move to an FDA-approved product, ask your prescriber about Mounjaro (tirzepatide) or Zepbound (tirzepatide). Those brand-name products are not part of these recalls.
Sources
- FDA Enforcement Report, Apothecary Pharma tirzepatide recall D-0036-2027 and NAD+ recall D-0037-2027: FDA openFDA drug enforcement record D-0036-2027
- FDA Enforcement Report, Houston Rx tirzepatide/niacinamide recall D-0040-2027: FDA openFDA drug enforcement record D-0040-2027
- FDA, Import Alert 66-80: Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances
- Health Law Alliance, Compounded GLP-1 Sourcing: Active Ingredient Suppliers Under Scrutiny
See our compounded GLP-1 guide for background on compounded GLP-1 safety, cost, and FDA guidance.



